NCT01966887View on ClinicalTrials.gov

AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

February 29, 2016

Conditions
Heart Failure CongestiveIschemic CardiomyopathyNon-ischemic Cardiomyopathy
Interventions
GENETIC

MYDICAR-single intracoronary infusion

AAV1/Serca2a

GENETIC

Placebo; single intracoronary infusion

single intracoronary infusion

Trial Locations (1)

75013

CHU Pitié-Salpêtrière, Paris

Sponsors

Collaborators (1)

Celladon Corporation
All Listed Sponsors
collaborator

Celladon Corporation

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01966887 - AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure | Biotech Hunter | Biotech Hunter